Leap Therapeutics, Inc. (NASDAQ:LPTX) issued its earnings results on Monday. The company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11), Bloomberg Earnings reports.

Shares of Leap Therapeutics (NASDAQ LPTX) traded up $0.14 during midday trading on Tuesday, hitting $6.25. The stock had a trading volume of 118,700 shares, compared to its average volume of 23,397. Leap Therapeutics has a twelve month low of $4.90 and a twelve month high of $10.10.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/11/14/leap-therapeutics-inc-lptx-issues-earnings-results-misses-estimates-by-0-11-eps.html.

Separately, Zacks Investment Research cut Leap Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Receive News & Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.